ATEM Capital will attend the 40th Annual J.P. Morgan Healthcare Conference in San Francisco, California. This premier conference is the largest and most informative health care investment symposium in the industry, which connects thousands of global industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.
The J.P. Morgan Healthcare Conference will be held January 10-13, 2022, at the Westin St. Francis Hotel in San Francisco, California.
ATEM Capital to Participate in 40th J.P. Morgan Healthcare Conference week
Amolyt Pharma announced that the company has been selected for the French Tech FT120, a support program for French late-stage startups by the French State. The French Tech 120 program identifies the 120 top-performing startups based in France. This year’s award included 7 biotechnology companies developing innovative therapies. The selection is based on financial criteria of fundraising or hypergrowth of sales. The globally renowned reputation of the French Tech 120 program will greatly benefit the company by providing increased visibility and a range of services.

Amolyt Pharma Selected for the French Tech 120 Program
Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that do not require gene editing and co-opt the natural biology of T cells to treat patients with solid tumors, today announced the presentation of preclinical data from its proof-of-concept study in gastric cancer. These new data demonstrate that Triumvira’s novel T cell antigen coupler (TAC)-T cell candidate targeting Claudin 18.2 (CLDN18.2) effectively eradicates CLDN18.2-expressing gastric tumor cells in vitro and in vivo.
Triumvira Announces Data from Gastric Cancer Preclinical Study

Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, announced positive results from its Phase 1 clinical trial of AZP-3601, a potential treatment for hypoparathyroidism, at the American Society for Bone and Mineral Research 2021 Annual Meeting. These findings showed that repeated injection of AZP-3601 to healthy volunteers resulted in a fast, dose-dependent increase in serum calcium levels that sustained throughout the treatment period. Furthermore, due to the unique mechanism of action of AZP-3601 and its short pharmacokinetic half-life, no increase in urine calcium excretion was detected, and bone biomarkers were unchanged.
Amolyt Pharma Announces Positive Phase 1 Trial Data
Triumvira Immunologics announced that the first patient has been dosed as part of the TACTIC-2 trial evaluating the company’s lead candidate, TAC01-HER2, an autologous T cell therapy for the treatment of human epidermal growth factor receptor 2 (HER2) positive solid tumors. “The initiation of our TACTIC-2 trial represents a significant milestone for Triumvira and an opportunity to establish clinical proof of concept for our TAC technology. We look forward to sharing our progress with this program as we build out a pipeline of candidates targeting solid tumors," said Paul Lammers, M.D., M.Sc., President and CEO of Triumvira.
Triumvira Doses First Patient with Novel T Cell Therapy in TACTIC-2 Clinical Trial
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, announced that the company had closed an $80 million Series B equity financing round. The financing was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital and all investors from the company’s July 2019 Series A financing, including LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation. The funds will be used to continue clinical development of AZP-3601 for hypoparathyroidism while progressing AZP-3813 through IND-enabling activities in acromegaly and further expanding early-stage pipeline.
Amolyt Pharma Closes an $80 million Series B Equity Financing Round
Iridia™, Inc., a pioneer in fully integrated DNA-based memory chips, announced that it had closed its Series B financing at a total of $24 million. The round, led by LifeSci Venture Partners of New York, was substantially oversubscribed, with other prominent participants including Western Digital Capital, JSR Corporation, North Sound Ventures, the Pritzker Vlock Family Office (PVFO), Longley Capital, Validus Growth Investors, ATEM Capital, Tech Coast Angels, and numerous industry-leading high net-worth individuals. Iridia’s disruptive technology is designed to integrate the writing, storage, and read back of massive amounts of data in a microchip format using synthetic DNA as the storage media. This combination of functionality will significantly increase data density and durability compared to conventional approaches, while dramatically reducing the physical and carbon footprints of commercial data centers around the world.
Iridia Raises $24 Million in Series B Funding